SOURCE: Leerink Swann & Company

August 05, 2005 06:00 ET

Leerink Swann & Company Initiates Coverage of Conor Medsystems, Inc. (NASDAQ: CONR)

BOSTON, MA -- (MARKET WIRE) -- August 5, 2005 -- Yesterday after the close, Senior Medical Device Analyst, Jason Wittes, initiated coverage of Conor Medsystems, Inc. with an Outperform rating. His investment rating is based on his belief that the company has designed the potentially best-in-class drug-eluting stent, which allows for easier control of drug kinetics as well as better efficacy and safety.

About Conor Medsystems, Inc.

Conor Medsystems, Inc. (NASDAQ: CONR) is a developer of innovative controlled vascular drug delivery technologies. Conor's current clinical efforts are focused on the development and commercialization of its CoStar™ stent which is a cobalt chromium paclitaxel-eluting stent for the treatment of restenosis. The company is headquartered in Menlo Park, California.

About Leerink Swann & Company

Leerink Swann & Company is an investment banking firm that provides healthcare equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2004 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. MEDACorp includes thousands of biomedical professionals and practicing physicians. Leerink Swann & Company is a member NASD/SIPC.

Contact Information

  • Contact:
    John I. Fitzgerald
    Leerink Swann & Company
    (617) 918-4564